Abstract:Under stress, the heart undergoes extensive remodeling resulting in cardiac fibrosis and hypertrophy, ultimately contributing to chronic heart failure (CHF). Alterations in microRNA levels are associated with dysfunctional gene expression profiles involved in the pathogenesis of heart failure. We previously showed that myocardial infarction-induced microRNA-enriched extracellular vesicles (EVs) contribute to the reduction in antioxidant enzymes by targeting Nrf2 signaling in CHF. MicroRNA-27a (miRNA-27a) is the predominant microRNA contained in cardiac fibroblast-derived EVs contributing to oxidative stress along with hypertrophic gene expression in cardiomyocytes. In the present study, we observed that miRNA-27a passenger strand (miRNA-27a*) was markedly upregulated in the non-infarcted area of the left ventricle of rats with CHF and encapsulated into EVs and secreted into the circulation. Bioinformatic analysis revealed that PDZ and LIM domain 5 (PDLIM5) is one of the major targets of miRNA-27a*, playing a major role in cardiac structure and function, and potentially contributing to the progression of cardiac hypertrophy. Our in vivo data demonstrate that PDLIM5 is down-regulated in the progression of heart failure, accompanied with the upregulation of hypertrophic genes and consistent with alterations in miRNA-27a*. Moreover, exogenous administration of miRNA27a* mimics inhibit PDLIM5 translation in cardiomyocytes whereas a miRNA27a* inhibitor enhanced PDLIM5 expression. Importantly, we confirmed that infarcted hearts have higher abundance of miRNA-27a* in EVs compared to normal hearts and further demonstrated that cultured cardiac fibroblasts secrete miRNA27a*-enriched EVs into the extracellular space in response to Angiotensin II stimulation, which inhibited PDLIM5 translation, leading to cardiomyocyte hypertrophic gene expression. In vivo studies suggest that the administration of a miRNA-27a* inhibitor in CHF rats partially blocks endogenous miR-27a* expression, prevents hypertrophic gene expression and improves myocardial contractility. These findings suggest that cardiac fibroblast-secretion of miRNA27a*-enriched EVs may act as a paracrine signaling mediator of cardiac hypertrophy that has potential as a novel therapeutic target.

MicroRNA miR-27a-3p accelerates cardiac hypertrophy by targeting neuro-oncological ventral antigen 1

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

MiR-27a-3p/Hoxa10 Axis Regulates Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting Kv4.3 Expression

MicroRNA-27 attenuates pressure overload-Induced cardiac hypertrophy and dysfunction by targeting galectin-3

MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling

Cardiomyocyte Overexpression of Mir-27B Induces Cardiac Hypertrophy and Dysfunction in Mice.

Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a

Extracellular Vesicular MicroRNA-27a* Contributes to Cardiac Hypertrophy in Chronic Heart Failure

Role of microRNAs in cardiac hypertrophy and heart failure.

MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.

The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy

Overexpression of Microrna-26B Attenuates Angiotensin II-induced Cardiac Hypertrophy Through Inhibition of Autophagic Responses.

Cardiac Hypertrophy is Positively Regulated by MicroRNA-24 in Rats

Microrna-327 Regulates Cardiac Hypertrophy And Fibrosis Induced By Pressure Overload

The Expression Of Microrna In Adult Rat Heart With Isoproterenol-Induced Cardiac Hypertrophy

Involvement of Microrna-23B-5p in the Promotion of Cardiac Hypertrophy and Dysfunction Via the HMGB2 Signaling Pathway.

Role of Micrornas in Cardiac Hypertrophy and Heart Failure

Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy

MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.

MicroRNA-34c-5p Provokes Isoprenaline-Induced Cardiac Hypertrophy by Modulating Autophagy Via Targeting ATG4B

miR-208a in Cardiac Hypertrophy and Remodeling